Rami Komrokji

Rami Komrokji

H. Lee Moffitt Cancer Center & Research Institute - Tampa / United States
Others
AD Scientific Index ID: 4927054
person_outline Rami Komrokji's MOST POPULAR ARTICLES
1-) Luspatercept in patients with lower-risk myelodysplastic syndromesP Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ...New England Journal of Medicine 382 (2), 140-151, 20203402020
2-) Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic SyndromesDA Sallman, AE DeZern, G Garcia-Manero, DP Steensma, GJ Roboz, ...Journal of Clinical Oncology 39 (14), 1584-1594, 20213782021
3-) Phase 2 trial of CPX-351, a fixed 5: 1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AMLJE Lancet, JE Cortes, DE Hogge, MS Tallman, TJ Kovacsovics, ...Blood, The Journal of the American Society of Hematology 123 (21), 3239-3246, 20143752014
4-) The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotypeAA Basiorka, KL McGraw, EA Eksioglu, X Chen, J Johnson, L Zhang, ...Blood, The Journal of the American Society of Hematology 128 (25), 2960-2975, 20163602016
5-) A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosisF Passamonti, T Giorgino, B Mora, P Guglielmelli, E Rumi, M Maffioli, ...Leukemia 31 (12), 2726-2731, 2017